Fig. 2
One-way sensitivity analysis of key parameters on the incremental cost-effectiveness ratio (ICER) per CRI case prevented in Beijing Trial 1 (2008/09) and Trial 2 (2009/10)
Fig. 2 | BMC Infectious Diseases
One-way sensitivity analysis of key parameters on the incremental cost-effectiveness ratio (ICER) per CRI case prevented in Beijing Trial 1 (2008/09) and Trial 2 (2009/10)